First AD

Second AD

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.

ASH 2023 Updates on Frontline Therapies in FL

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Recent Updates in the Treatment of Follicular Lymphoma and Mantle Cell Lymphoma

Peer Exchange

Mayo Clinic

Cancer Centers

Partner

Dana-Farber Cancer Institute

Weill Cornell Medical College Sandra & Edward Meyer Cancer Center

Moffitt Cancer Center

Current Treatment Options in First-line FL

Current Treatment Options in Second-line FL

CAR T-cells as Third-line and Beyond Therapy for FL

Bispecific T-cell Engagers as Third-line and Beyond Therapy for FL

Tazemetostat as Third-line and Beyond Therapy for FL

Zanubrutinib as Third-Line and Beyond Therapy for FL

Choosing Bispecific T-cell Engager as Third-line and Beyond Therapy for FL

Choosing CAR T-cells as Third-line and Beyond Therapy for FL

Sequencing Immunotherapy in the Third-line and Beyond Setting for FL

Unmet Needs in Treating Relapsed/Refractory FL

Current Treatment Options in First-Line MCL

ASH 2023 Updates on Frontline Therapies in MCL

Current Treatment Options in Second-line MCL

Current Treatment Options in Third-line MCL

Sequencing Therapies in the Third-Line and Beyond Setting for MCL

Future Directions and Unmet Needs in Relapsed/Refractory MCL